Translational research engine for longevity

The first human step, done right.

Exploratory human proof-of-mechanism for companies targeting the hallmarks of aging. First human signal, in months.

Discuss a study → How it works
The problem

The first human step is where longevity companies get stuck.

  • Companies targeting a hallmark of aging reach their key value-inflection point with only mechanism and mice.
  • Generic CROs were not built for exploratory longevity work: slow, expensive, indication-agnostic, and weakest exactly where it matters, at recruiting the right subjects.
  • The result is a stalled value-inflection point, and a raise that stays harder than it should be.
What we do

Fast, rigorous, biomarker-anchored exploratory trials.

Generic CROs were not built for exploratory longevity work. We are a human proof-of-mechanism platform for longevity, built for exactly this.

A launch focus that measures

Muscle and functional aging, anchored on VO2 max and CPET, DXA, strength and gait, and metabolic and mitochondrial biomarkers.

Objective endpoints

A trial-ready cohort

A deeply-phenotyped, trial-ready cohort means we do not recruit, we already have them. Enrollment measured in weeks, not quarters.

Weeks, not quarters

Rigor patients can trust

Sponsors pay; patients enroll as subjects and never pay to be in a study. Rigorous, IRB-approved, PI-led.

Sponsors pay, never patients

A publishable data package

Credible, publishable human proof-of-mechanism in months, contextualized against a growing benchmark of prior compounds.

Proof-of-mechanism
Why now

The market pays a premium for clinical data.

~2x
First clinical data roughly doubles a company's valuation.
Phase 1 to Phase 2 uplift, ~1.8x to 2.7x. Michaeli et al.; BayBridgeBio rNPV; BIO probability-of-approval.
$72M
Average clinical-stage round, versus $52M for early-stage.
Alvarez & Marsal, 2026. Capital has turned selective and data-driven.
68%
Of biopharma M&A targets Phase II and later assets.
Alvarez & Marsal, 2026. Venture is running strong but selective (Stifel, 2026).

Generating early human data has become the price of admission to premium capital. Waypoint exists to produce that data credibly, quickly, and at a fraction of the usual friction.

Why us

The moat is the benchmark.

Independence and rigor make the data trusted. Standardization makes it compound.

01

Trusted by design

Scientific rigor and an independent, credible brand: data that sponsors and their investors trust because we do not sell the compound.

02

Data that appreciates

Standardized panels across every study build a proprietary reference dataset that shows how each compound ranks. It appreciates with every study and cannot be replicated by a one-off clinic.

03

A platform, not a clinic

A multi-site network plus an owned, trial-ready cohort. Clinics are delivery nodes; the data, protocols, and brand stay with us.

04

High velocity, compounding

Many small studies at high velocity. Each study sharpens the benchmark and makes the next read-out more valuable.

How it works

Four steps, from protocol to raise.

1

Design

We build the exploratory protocol and the biomarker and target-engagement strategy.

2

Run

Fast enrollment from the trial-ready cohort, strict follow-up, standardized panel.

3

Read out

Objective biomarker signal, contextualized against our benchmark of prior compounds.

4

Deliver

A credible, publishable data package that sharpens the indication and de-risks the next raise.

Who it's for

Built for the value-inflection point.

Early longevity and biotech companies at a value-inflection point, especially those targeting a hallmark of aging that have not yet locked a final indication. If your key step is first human proof-of-mechanism, this is what we do.

JN

Jose Navarro-Betancourt

MD, PhD · Founder
Credibility

A rigorous evaluator, not a vendor.

Founded by a physician-scientist. Waypoint is led by Jose Navarro-Betancourt, MD, PhD, and built around a single commitment: objective human data that stands up to scrutiny.

Clinical delivery runs through partner concierge clinics with licensed principal investigators. Every study is IRB-approved and PI-led. We measure, we do not market.

Let's discuss a study.

If you are approaching first-in-human and need credible data to de-risk and raise, we should talk. Exploratory, biomarker-anchored, in months.

Discuss a study →